Clinical Trial: Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study
Brief Summary: This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with Atypical Alzheimer's Disease and how burden may change over a two-year period.
Detailed Summary:
Sponsor: Mayo Clinic
Current Primary Outcome:
- Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]
- Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]
Original Primary Outcome:
- Amount of Amyloid protein in the brain of patients with LPA or PCA. [ Time Frame: 5 years ]
- Amount of Tau protein in the brain of patients with LPA or PCA. [ Time Frame: 5 years ]
Current Secondary Outcome:
- Rates of change in amyloid-PET burden over time. [ Time Frame: baseline, 2 years ]
- Rates of change in tau-PET burden over time. [ Time Frame: baseline, 2 years ]
Original Secondary Outcome: Same as current
Information By: Mayo Clinic
Dates:
Date Received: April 7, 2016
Date Started: May 2016
Date Completion: March 2021
Last Updated: December 22, 2016
Last Verified: December 2016